Has Ramon Flores, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,484 in general payments to Ramon Flores, MD across 48 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ramon Flores, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ramon Flores, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ramon Flores, MD

Pulmonary Disease · San Juan, PRNPI 1447200951

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 63.8% of it on its own, with 10 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in PR, where the typical reported total is $2,361.

$1,484in general payments, 2019–2025

Across 48 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$947
Merck$139
Mallinckrodt Hospital Products Inc.$100
Boehringer Ingelheim$83
Mylan Specialty L.p.$63
Genentech USA, Inc.$49
plus $103 from 5 others

$84,340in research payments, 2019–2025

Across 4 payments — averaging $21,085 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$84K

What the payments were for

Food & beverage$1,36692%
Education$1188%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	34	$947
Merck	2	$139
Mallinckrodt Hospital Products Inc.	1	$100
Boehringer Ingelheim	3	$83
Mylan Specialty L.p.	2	$63
Genentech USA, Inc.	1	$49
United Therapeutics Corporation	1	$35
Johnson & Johnson	1	$25
Bayer	1	$18
Mylan LLC	1	$13
GSK	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BREZTRI$237
JANUMET$100

How this compares

$1,484 in reported general payments places this provider in the 30th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$14,409

Medicare patients

Services billed

156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AdempasRiociguat	36	$502,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	624	$416,248
OpsumitMacitentan	13	$160,128
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	392	$100,249
Breo ElliptaFluticasone/Vilanterol	166	$69,384
Pirfenidone	16	$54,406
Stiolto RespimatTiotropium Br/Olodaterol Hcl	98	$47,858
Breztri AerosphereBudesonide/Glycopyr/Formoterol	67	$44,707
SymbicortBudesonide/Formoterol Fumarate	154	$36,120
Fluticasone Propionate HfaFluticasone Propionate	80	$24,026
Spiriva RespimatTiotropium Bromide	41	$22,855
Wixela InhubFluticasone Propion/Salmeterol	106	$21,983
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	35	$18,612
Albuterol Sulfate HfaAlbuterol Sulfate	434	$18,355
Advair HfaFluticasone Propion/Salmeterol	31	$10,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta	$12	$504,244825 claims
BayerAdempas	$18	$502,78936 claims
AstraZenecaBreztri Aerosphere, Symbicort	$947	$80,826221 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat	$83	$70,713139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →